Betta Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Betta Pharmaceuticals Co., Ltd., explained in plain language.
Chinese pharmaceutical company focused on oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug duo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for lung cancer patients whose drugs have failed
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer that has stopped responding to a type of targeted therapy called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug called befotertinib, can help con…
Phase: PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC